Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.37 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.37 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.37 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.37 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.35 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.35 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.35 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.35 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.35 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.33 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6613546 | 0.85 | ALDH1A1 (0.42) | MEN1KMT2AHTR2ADRD3ADRA2A | |
| SCHEMBL6611465 | 0.84 | HDAC1 (0.38) | MCHR1 | |
| SCHEMBL13592435 | 0.84 | GRIA1 (0.34) | MEN1KMT2ADRD3ADRA2AADRA2B | |
| SCHEMBL6608100 | 0.81 | HRH4 (0.39) | HTR6HRH4GRIA1GRIA2GRIA3 | |
| SCHEMBL6608260 | 0.78 | KDM4E (0.43) | MEN1KMT2AHTR2ADRD3ADRA2A | |
| SCHEMBL4394396 | 0.78 | HTR6 (0.47) | MEN1KMT2AHTR6DRD2HTR2A | |
| SCHEMBL8142621 | 0.77 | CYP3A4 (0.43) | MEN1KMT2AHRH3CYP2D6CYP1A2 | |
| SCHEMBL4363232 | 0.76 | HTR2A (0.51) | MEN1KMT2AHTR6DRD2HTR2A | |
| SCHEMBL8136163 | 0.74 | MAPK1 (0.49) | MEN1KMT2AHRH3POLBCYP1A2 | |
| SCHEMBL8232020 | 0.72 | CYP2C19 (0.39) | MEN1KMT2ADRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-7282511-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | disclosed |
| EP-1255734-B1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH AS (DK) | 2006-06-21 | — | — | EP | disclosed |
| EP-0869958-B1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| EP-1066037-B1 | USE OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES AS AMPA ANTAGONISTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| US-6693111-B1 | 1H-PYRROLO(3,2-H)ISOQUINOLINE DERIVATIVES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | NEUROSEARCH A/S (DK) | 2004-02-17 | — | — | US | disclosed |
| US-RE38200-E1 | Capable of antagonizing effect of excitatory amino acids, such as glutamate | NEUROSEARCH A/S (DK) | 2003-07-22 | — | — | US | disclosed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | disclosed |
| US-5917053-A | INHIBITING GABA RELEASE FROM NEURONS | NEUROSEARCH A/S (DK) | 1999-06-29 | — | — | US | disclosed |
| US-5843945-A | AMPA antagonists and a method of treatment | NEUROSEARCH A/S (DK) | 1998-12-01 | — | — | US | disclosed |
| EP-0869958-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| US-5780493-A | TREATING BRAIN DISORDERS | NEUROSEARCH A/S (DK) | 1998-07-14 | — | — | US | disclosed |
| WO-1998014447-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-04-09 | — | — | WO | disclosed |
| EP-0698025-B1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH AS (DK) | 1997-12-17 | — | — | EP | disclosed |
| EP-0781284-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008494-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
| EP-0698025-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026747-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | HTR6 1482/4885DRD2 671/4885HTR2A 1309/4885 |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | HTR6 1482/4885DRD2 671/4885HTR2A 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.